Transdermal Estrogen Is Good For Hot Flash Mitigation and For Hormone Therapy (ADT)

Yesterday's post about the use of transdermal estrogen patches as an alternative to LHRHa drugs  elicited a question on the Malecare Health Unlocked Advanced Prostate Cancer Online Support Group.  The question raised, or I should say the comment made was that estrogen is used for the purposes of hot flash mitigation and the use of [...]

Comparison Evaluating Bone Mineral Density Changes in Advanced Prostate Cancer: Luteinising Hormone-releasing Hormone Agonists Versus Transdermal Oestradiol

The current standard hormone therapy (ADT) for men with advanced prostate cancer is a class of drugs called Luteinising hormone-releasing hormone agonists (LHRHa). These drugs reduce serum oestradiol as well as testosterone, causing bone mineral density (BMD) loss as a side effect of the ADT. Using transdermal (skin patches) oestradiol is a potential alternative to [...]

What You Need to Know About Xgeva or Denosumab

Xgeva, also known as denosumab, is an injectable medication (injected once a month subcutaneously under the skin in the doctor’s office) that is used to prevent bone fractures and spinal cord compression caused by bone metastases in breast and prostate cancer survivors. Solid tumors in the bone, which is a common site for individuals with [...]

Skeletal Events and the Treatment of Men with Advanced Prostate Cancer

Many of our doctors are constantly vigilant about our developing skeletal related issues.   Having advanced prostate cancer and receiving treatment for this disease increases our odds of developing skeletal issues which affect both our quality of life and our mortality. Drugs like denosumab (Xgeva) and zoledronic acid (Zometa) are important in delaying the onset of [...]

It Maybe Time To Change The Dosing Schedule Of Zoledronic Acid To Every 12 Weeks

In a presentation at the ASCO Annual Meeting,  Dr. Andrew Himelstein, MD, FACP of the Helen F. Graham Cancer Center & Research Institute, presented the results of a trial evaluating Zoledronic Acid (Zometa) at a dosing schedule of every 12 weeks as opposed to the current standard of care of every 4 weeks. The trial included [...]

Clinical Trial Evaluates Hormone Therapy With And Without Zoledronic Acid In Men With Prostate Cancer And Bone Metastases Who Are Treatment-Naïve

Zoledronic acid (ZA) is considered the standard of care to prevent skeletal-related events (SREs) in men with castration-resistant prostate cancer and bone metastases. The question that still remains is when to start the ZA. In a phase III clinical trial a total of 227 men with hormonal treatment-naïve prostate cancer and bone metastases were randomly [...]

Understanding the Complexities of Bone Metastases in Prostate Cancer

Our bones operate in a balanced and dynamic system, which in the normal situation keep them strong. Bones are constantly being eliminated and then remade to keep them healthy and read to support our frame. This normal process involves two major kinds of bone cells that work together, in balance, to keep bones healthy and [...]

Radiologic Progression Free Survival Might Predict Treatment Response and Survival

In a recent publication it was suggested that radiographic progression-free survival (rPFS) in men with metastatic castration-resistant prostate cancer (mCRPC) was highly consistent and highly associated with overall survival. This reproducible quantitative find could have implications for the interim measurement of treatment response in future studies, according to Dr. Michael J. Morris of Memorial Sloan [...]

Bone Complications Among Prostate Cancer Survivors Having Prolonged Hormone Therapy (ADT)

Androgen deprivation therapy (ADT) and bone complications are the two near universals for men with advanced prostate cancer. A long-term follow up of fifteen (15) years after diagnosis of a population-based cohort of prostate cancer survivors proved to be very informative. The Prostate Cancer Outcomes Study, which enrolled 3533 men diagnosed with prostate cancer between [...]

Randy Sheffield Shares An Important Warning About ONJ

Randy Sheffield, a member of the Malecare Advanced Prostate Cancer Online support group recently has had his fight with advanced prostate cancer made even more complex when he developed Osteonecrosis of the jaw (ONJ). ONJ is an uncommon but terrible side effect of taking bisphosphonates. Randy wrote a warning to all the members of the [...]